Copyright
©The Author(s) 2021.
World J Hepatol. Jan 27, 2021; 13(1): 80-93
Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.80
Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.80
Author, year | Population, study design, sample size | Prevalence of NAFLD in lean subjects | Main findings |
Zou et al[4], 2020 | Mixed population, 1999-2016 NHANES databases | 32.3% overall NAFLD prevalence; 22.7% obese and 9.6% non-obese; Amongst NAFLD patients, 29.7% were non-obese (Caucasian BMI 25-30 kg/m2, Asian BMI 23-27 kg/m2), of which 13.6% had lean NAFLD (Caucasian BMI < 25 kg/m2, Asian BMI < 23 kg/m2) | Non-obese NAFLD individuals had higher 15-year cumulative all-cause mortality (51.7%) than obese NAFLD (27.2%) and non-NAFLD (20.7%) |
Huang et al[20], 2020 | 2483 Asian participants, community based study | 44.5% NAFLD and 15.8%, MetS prevalence; Among NAFLD subjects, 48.8%were obese (BMI ≥ 24 kg/m2) | IR is predictive of NAFLD irrespective of BMI; CV risk calculated by Framingham Risk Score may exist in lean NAFLD subjects |
Tobari et al[18], 2020 | Asian, biopsy-proven 762 NAFLD patients, cross sectional study | Over 25% men and almost 40% women were non-obese, but most of them had visceral fat obesity and/or IR; BMI cutoff 25 kg/m2 | NAFLD was not milder in non-obese patients; Histological steatosis was associated with BMI; Advanced fibrosis was not associated with BMI and showed a significant sex difference |
Kim et al[10], 2020 | 664 Asian subjects with biopsy-proven NAFLD and controls, cross sectional study | 542 subjects with biopsy-proven NAFLD132 non-obese NAFLD (BMI < 25 kg/m2) ; 410 obese NAFLD (BMI > 25 kg/m2) ; 122 controls | Non-obese subjects with NAFLD displayed a similar severity of histological liver damage; Sagittal abdominal diameter was independently associated with significant fibrosis among subjects with non-obese NAFLD |
Alferink et al[71], 2019 | 4609 elderly European, population based study | 1623 had NAFLD (n = 161 normal-weight and n = 1462 overweight, BMI cutoff 25 kg/m2) | Both high fat mass and low SMI were associated with normal-weight NAFLD; Fat distribution (assessed by AGR) could best predict NAFLD prevalence |
Denkmayr et al[19], 2018 | European, 466 patients diagnosed with NAFLD, cross sectional study | Lean (BMI ≤ 25.0 kg/m², n = 74) ; Overweight (BMI > 25.0 ≤ 30.0 kg/m², n = 242) ; Obese (BMI > 30.0 kg/m², n = 150) | Lean NAFLD patients had a histological picture similar to obese patients but more severe compared to overweight patients. |
Gonzalez-Cantero et al[21], 2018 | European, cross-sectional study 113 non-obese, non-diabetic individuals | 55 patients diagnosed with NAFLD; NAFLD defined as hepatic triglyceride content > 5.56% (quantified by 3T H1-MRS) ; BMI cutoff 25 kg/m2 | Lean-with-NAFLD group had significantly higher HOMA-IR and lower serum adiponectin than the overweight-without-NAFLD group; IR was independently associated with NAFLD but not with waist circumference or BMI |
Hagström et al[5], 2017 | European, prospective cohort study of 646 patients with biopsy-proven NAFLD | 19% lean NAFLD; 52% overweight NAFLD; 29% obese NAFLD; BMI cutoff 25 and 30 kg/m2 | Lean NAFLD had lower stages of fibrosis and higher risk for severe liver disease development compared to patients with NAFLD and a higher BMI, independent of available confounders (follow-up 19.9 years) |
Leung et al[6], 2017 | Asian, prospective, 307 NAFLD patients | 23.5% were non-obese; BMI cutoff 25 kg/m2 | Non-obese NAFLD patients have less-severe disease and may have a better prognosis than obese patients; Hypertriglyceridemia and higher creatinine are the key factors associated with advanced liver disease in non-obese patients |
Fracanzani et al[11], 2017 | European, retrospective cohort study of 669 patients with biopsy-proven NAFLD | 143 patients had BMI < 25 kg/m2 and NAFLD | 20% of patients with lean NAFLD have NASH, fibrosis scores of 2 or higher, and carotid atherosclerosis |
Feldman et al[22], 2017 | Caucasian, cross sectional, 187 subjects with hepatic steatosis on ultrasound | Lean healthy (BMI ≤ 25 kg/m2, no steatosis, n = 71) ; Lean NAFLD (BMI ≤ 25 kg/m2, steatosis, n = 55) ; obese NAFLD (BMI ≥ 30 kg/m2, steatosis; n = 61) | Lean NAFLD have impaired glucose tolerance, low adiponectin concentrations and an increased rate of PNPLA3 risk allele carriage |
Feng et al[7], 2014 | Asian, population based, 1779 participants | The prevalence of NAFLD was 18.33% in the lean group and 72.90% in the overweight-obese groupBMI cutoff 24 kg/m2 | Lean-NAFLD was more strongly associated with diabetes, hypertension, and MetS than overweight-obese-NAFLD; NAFLD patients were more likely to have central obesity especially in lean groups |
Younossi et al[17], 2012 | Mixed population, 1988-1994 NHANES databases | 2185 (18.77% ± 0.76%) of subjects had NAFLD; 7.39% ± 0.65% had lean NAFLD; 27.75% ± 1.00% had overweight/obese NAFLDBMI cutoff 25 kg/m2 | Lean NAFLD was independently associated with younger age, female sex, and a decreased likelihood of having IR and hypercholesterolemia |
Margariti et al[16], 2012 | European, cross sectional, 162 NAFLD patients | Normal BMI was present in 12% of patients; BMI cutoff 25 kg/m2 | Lean NAFLD patients do not have IR-associated metabolic disorders, but they have higher levels of ALT/AST than the overweight or obese NAFLD patients |
Definitions of metabolic health in non-obese individuals: | |
Absence of insulin resistance | Meigs et al[62]; Stefan et al[63] |
Absence of insulin resistance and low CRP levels as a surrogate marker for inflammation, in combination with up to any two parameters of metabolic syndrome | Wildman et al[64]; Karelis et al[65] |
Combination with up to any two parameters of metabolic syndrome | Stefan et al[66]; Phillips[67] |
Definition of metabolically unhealthy non-obese individuals: | |
BMI < 25 kg/m2 and presence of insulin resistance | Stefan et al[23] |
Waist circumference adjusted for BMI and/or android gynoid ratio and presence of insulin resistance | Suggested by authors |
- Citation: Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals . World J Hepatol 2021; 13(1): 80-93
- URL: https://www.wjgnet.com/1948-5182/full/v13/i1/80.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i1.80